Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vor BiopharmaVOR +4.02%32 Equity-to-Asset is -0.30 as of Mar. 2026. GuruFocus rates VOR with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 1,416 Biotechnology companies, Vor Biopharma ranks worse than 89.97% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Vor Biopharma's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $-150.42 Mil. Vor Biopharma's Total Assets for the quarter that ended in Mar. 2026 was $506.75 Mil.
The historical rank and industry rank for Vor Biopharma's Equity-to-Asset or its related term are showing as below:
VOR'
s Equity-to-Asset Range Over the Past 10 Years
Min: -12.63 Med: 0.76 Max: 0.91
Current: -0.3
During the past 8 years, the highest Equity to Asset Ratio of Vor Biopharma was 0.91. The lowest was -12.63. And the median was 0.76.
VOR's Equity-to-Asset is ranked worse than 89.97% of 1416
companies
in the Biotechnology industry
Industry Median: 0.68
vs VOR: -0.30
Vor Biopharma (NAS:VOR) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Vor Biopharma Equity-to-Asset Related Terms
Vor Biopharma Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Vor Biopharma's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VOR vs ANRO, CGEM, OLMA: Equity-to-Asset Comparison
For the Biotechnology subindustry, Vor Biopharma's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vor Biopharma Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vor Biopharma's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Vor Biopharma's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Vor Biopharma's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vor Biopharma (VOR) has a Equity-to-Asset of -0.30 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Vor Biopharma and its competitors. According to the industry distribution chart, Vor Biopharma ranks #1274 out of 1416 companies in the Biotechnology industry, placing it in the top 90%.
Is Vor Biopharma's Equity-to-Asset too high?
Vor Biopharma's current Equity-to-Asset is -0.30. Based on the distribution chart, Vor Biopharma ranks #1274 out of 1416 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vor Biopharma has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Vor Biopharma's Equity-to-Asset compare to ANRO and CGEM?
According to the Biotechnology industry distribution chart, Vor Biopharma ranks #1274 out of 1416 companies for Equity-to-Asset. This places Vor Biopharma in the lower half of its industry. The industry median Equity-to-Asset is 0.68. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Vor Biopharma and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vor Biopharma's current Equity-to-Asset is -0.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vor Biopharma stock overvalued right now?
Vor Biopharma (VOR) has a current Equity-to-Asset of -0.30. The current Equity-to-Asset is -0.30. Vor Biopharma's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Vor Biopharma (VOR), the current Equity-to-Asset is -0.30 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.
32GF Score
Get the complete analysis for VOR
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VOR has been successfully added to your 
